Skip to main content
SpringerLink
Log in

AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

We assessed whether upregulation of the angiotensin II (AngII) type 2 receptor (AT2R) during AngII type 1 receptor (AT1R) blockade might induce apoptosis in the in vivo rat model of reperfused myocardial infarction (RMI) and whether addition of an AT2R blocker abolishes that effect. We measured in vivo hemodynamics and left ventricular (LV) systolic and diastolic function (echocardiograms/Doppler), and ex vivo infarct size (triphenyl tetrazolium chloride), regional AT1R and AT2R proteins (immunoblots), and apoptosis (TUNEL assay and DNA ladder) after regional anterior RMI (60 min ischemia, 90 min reperfusion) in Sprague-Dawley rats randomized to intravenous AT1R blockade with candesartan (1 mg/kg, n= 9) or saline (controls, n= 14) over 30 min before RMI, and sham (n= 8). We also assessed the effect of AT2R blockade (PD123319, 10 mg/kg i.v.) plus candesartan on infarct size and apoptosis. Compared to controls, candesartan significantly (p < 0.001) limited increases in left atrial pressure, improved positive LV dP/dt max and negative dP/dt min, normalized LV ejection fraction, improved LV diastolic function, limited infarct expansion, decreased infarct size and apoptosis, and increased AT2R protein (not AT1R) in the reperfused ischemic zone. There were no changes in sham hearts. PD123319 abolished the candesartan-induced decrease in infarct size and LV dysfunction but not the decrease in apoptosis. Thus, during AT1R blockade in the in vivo rat model of RMI, regional AT2R upregulation contributes to the beneficial effect on infarct size and LV dysfunction but not on apoptosis, suggesting that the apoptosis is AT1R not AT2R-mediated. (Mol Cell Biochem 262: 203–214, 2004)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet359: 995–1003, 2002

    Article  PubMed  Google Scholar 

  2. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol.Lancet 359: 1004–1010, 2002

    Article  PubMed  Google Scholar 

  3. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675, 2001

    Article  PubMed  Google Scholar 

  4. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE III, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A Jr, Gregoratos G, Smith SC Jr: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100: 1016–1030, 1999

    PubMed  Google Scholar 

  5. Reimer KA, Jennings RB: The 'wavefront phenomenon' of myocardial ischemic cell death. II: Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40: 633–644, 1979

    PubMed  Google Scholar 

  6. Jugdutt BI: Effect of reperfusion on ventricular mass, topography and function during healing of anterior infarction.AmJ Physiol 272: H1205–H1211, 1997

    Google Scholar 

  7. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 66: 1146–1149, 1982

    PubMed  Google Scholar 

  8. Bolli R: Mechanism of myocardial stunning. Circulation 82: 723–738, 1990

    PubMed  Google Scholar 

  9. Ganz P, Ganz W: Coronary blood flow and myocardial ischemia. In: E. Braunwald, D.P. Zipes, P. Libby (eds.). Heart Disease. 6th edn. W.B.Saunders Company, Philadelphia, Vol 2, 2001, pp 1087–1113

    Google Scholar 

  10. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemiareperfusion injury. Am Heart J 128: 1–6, 1994

    Article  PubMed  Google Scholar 

  11. Youhua Z, Shouchun X: Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac reninangiotensin system. Chin Med J 108: 28–32, 1995

    PubMed  Google Scholar 

  12. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205–251, 1993

    PubMed  Google Scholar 

  13. Jugdutt BI: Role of AT1 receptor blockade in reperfused myocardial infarction. In: N.S. Dhalla (ed). Signal Transduction and Cardiac Hypertrophy.Kluwer Academic Publishers, Boston, 2002, pp 221–236

    Google Scholar 

  14. Zhu B, Sun Y, Sievers RE, Browne AE, Pulukurthy S, Sudhir K, Lee RJ, Chou TM, Chatterjee K, Parmley WW: Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 35: 787–795, 2000

    Article  PubMed  Google Scholar 

  15. Jalowy A, Schulz R, Dörge H, Behrends M, Heusch G: Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32: 1787–1796, 1998

    Article  PubMed  Google Scholar 

  16. Shimizu M, Wang QD, Sjoquist PO, Ryden L: The angiotensin IIAT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 13: 347–353, 1999

    Article  PubMed  Google Scholar 

  17. Xu Y, Menon V, Jugdutt BI: Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-ein acutely reperfused myocardial infarction.Effect of UP269-6 and losartan on AT1 and AT2 receptor expression, and IP3 receptor and PKCeproteins. J Renin Angiotensin Aldosterone Syst 1: 184–195, 2000

    PubMed  Google Scholar 

  18. Jugdutt BI, Xu Y, Balghith M, Moudgil R, Menon V: Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: 213 Association with regional increase in AT2R, IP3R and PKCeproteins and cGMP. J Cardiovasc Pharmacol Therapeut 5: 301–311, 2000

    Google Scholar 

  19. Jugdutt BI, Balghith M: Enhanced regional AT2-receptor and PKCeexpression during cardioprotection induced by AT1-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst 2: 134–140, 2001

    PubMed  Google Scholar 

  20. Miyoshi H, Takayama Y, Kitashiro S, Izuoka T, Saito D, Imuro Y, Mimura J, Yamamoto S, Tokioka M, Iwasaka T: Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs. Jpn J Pharmacol 89: 120–125, 2002

    Article  PubMed  Google Scholar 

  21. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T: Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369–1380, 1993

    Article  PubMed  Google Scholar 

  22. Hanatani A, Yoshiyama M, Takeuchi K, Kim S, Nakayama K, Omura T, Iwao H, Yoshikawa J: Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats. Jpn J Pharmacol 78: 45–54, 1998

    Article  PubMed  Google Scholar 

  23. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography.Hypertension 33: 961–968, 1999

    PubMed  Google Scholar 

  24. Xia QG, Chung O, Spitznagel H, Illner S, Janichen G, Rossius B, Gohlke P, Unger T: Significance of timing of angiotensinAT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res 49: 110–117, 2001

    Article  PubMed  Google Scholar 

  25. van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, Schalekamp MA: Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30: 42–49, 1997

    PubMed  Google Scholar 

  26. Wiemer G, Scholkens BA, Busse R, Wagner A, Heitsch H, Linz W: The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 3: 24–27, 1993

    Google Scholar 

  27. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926–1935, 1997

    PubMed  Google Scholar 

  28. Regitz-Zagrosek V, Auch-Shwelk W, Neuss M, Fleck E: Regulation of angiotensin receptor subtypes in cell cultures, animal models and human diseases. Eur Heart J 15: 92–97, 1994

    PubMed  Google Scholar 

  29. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M: Regulation and gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95: 46–54, 1995

    PubMed  Google Scholar 

  30. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RA, Suzuki T, Morgan K, Polak JM, Poole-Wilson PA: Regional changes in angiotensin II receptor density after experimental myocardial infarction.J Mol Cell Cardiol 28: 429–440, 1996

    Article  PubMed  Google Scholar 

  31. Sun Y, Weber KT: Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 28: 1623–1628, 1994

    PubMed  Google Scholar 

  32. Xu Y, Kumar D, Dyck J, Ford WR, Clanachan AS, Lopaschuk GD, Jugdutt BI: AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol 282: H1206–H1215, 2002

    Google Scholar 

  33. Moudgil R, Musat-Marcu S, Xu Y, Kumar D, Jugdutt BI: Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade. Can J Cardiol 18: 1107–1116, 2002

    PubMed  Google Scholar 

  34. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93: 156–160, 1996

    Article  PubMed  Google Scholar 

  35. Jugdutt BI, Joljart MJ, Khan MI: Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. Circulation 94: 94–101, 1996

    PubMed  Google Scholar 

  36. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE: Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92: 926–934, 1995

    PubMed  Google Scholar 

  37. Matsumura K, Jeremy RW, Schaper J, Becker LC: Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 97: 795–804, 1998

    PubMed  Google Scholar 

  38. Feigenbaum H, Popp RL, Wolfe SB, Troy BL, Pombo JF, Haine CL, Dodge HT: Ultrasound measurements of the left ventricle. A correlative study with angiocardiography. Arch Intern Med 129: 461–467, 1972

    Article  PubMed  Google Scholar 

  39. Balghith M, Jugdutt BI: Assessment of diastolic dysfunction after acute myocardial infarction using Doppler Echocardiography. Can J Cardiol 18: 69–77, 2001

    Google Scholar 

  40. Zaugg M, Jamali NZ, Lucchinetti E, Shafiq SA, Siddiqui MA: Norepinephrine-induced apoptosis is inhibited in adult rat ventricular myocytes exposed to volatile anesthetics. Anesthesiology 93: 209–218, 2000

    Article  PubMed  Google Scholar 

  41. Moudgil R, Menon V, Xu Y, Musat-Marcu S, Kumar D, Jugdutt BI: Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolatedworking rat hearts. J Hypertens 19: 1121–1129, 2001

    Article  PubMed  Google Scholar 

  42. Gohlke P, Pees C, Unger T: AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349–355, 1998

    PubMed  Google Scholar 

  43. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP: Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40: 244–250, 2002

    Article  PubMed  Google Scholar 

  44. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613–621, 1999

    PubMed  Google Scholar 

  45. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro.J Moll Cell Cardiol 29: 859–870, 1997

    Article  Google Scholar 

  46. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74: 86–107, 1996

    PubMed  Google Scholar 

  47. Dörge H, Behrends M, Schulz R, Jalowy A, Heusch G: Attenuation of myocardial stunning by the AT1 receptor antagonist candesartan. Basic Res Cardiol 94: 208–214, 1999

    Article  PubMed  Google Scholar 

  48. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, Fujiwara T, Fujiwara H: “Apoptotic” myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation. Analysis by immunogold electron microscopy combined with in situ nick endlabeling.Circulation 98: 1422–1430, 1998

    PubMed  Google Scholar 

  49. Kockx MM, Muhring J, Knaapen MWM, de Meyer GRY:RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol 152: 885–888, 1998

    PubMed  Google Scholar 

  50. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, Noda T, Fujiwara T, Fukuda K, Minatoguchi S, Fujiwara H: Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy. Not apoptosis but DNA repair.Circulation 99: 2757–2764, 1999

    PubMed  Google Scholar 

  51. Jugdutt BI, Warnica JW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: Effect of timing, dosage and infarct location. Circulation 78: 906–919, 1988

    PubMed  Google Scholar 

  52. Jugdutt BI: Identification of patients prone to infarct expansion by the degree of regional shape distortion on an early two-dimensional echocardiogram after myocardial infarction. A prospective study. Clin Cardiol 13: 28–40, 1990

    PubMed  Google Scholar 

  53. Lu L, Ko E, Schwartz GG, Chou TM: Transesophageal echocardiography in rats using an intravascular ultrasound catheter. Am J Physiol 273: H2078–H2082, 1997

    PubMed  Google Scholar 

  54. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063–3070, 1999

    PubMed  Google Scholar 

  55. Widdop RE, Jones ES, Hannan RE, Gaspari TA: AngiotensinAT2 receptors: Cardiovascular hope or hype? Br J Pharmacol 140: 809–824, 2003

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine and the Cardiovascular Research Group, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada

    Bodh I. Jugdutt & Vijayan Menon

Authors
  1. Bodh I. Jugdutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vijayan Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jugdutt, B.I., Menon, V. AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat. Mol Cell Biochem 262, 203–214 (2004). https://doi.org/10.1023/B:MCBI.0000038236.59905.8b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:MCBI.0000038236.59905.8b

Search

Navigation